



Datasheet for ABIN988237

SPARC Protein



[Go to Product page](#)

Overview

Quantity: 50 µg

Target: SPARC

Origin: Human

Source: Escherichia coli (E. coli)

Product Details

Sequence: MSYYHHHHHH DYDIPTTENL YFQGAMGSAP QQEALPDETE VVEETVAEVT EVSGANPVQ
VEVGEGFDDGA EETEEEVVAE NPCQNHHCKH GKVCELDENN TPMCVCQDPT SCPAPIGEFE
KVCSDNDKTF DSSCHFFATK CTLEGTKKGH KLHLDYIGPC KYIPPCLDSE LTEFPLRMRD
WLKNVLVTLY ERDEDNNLLT EKQKLRVKKI HENEKRLEAG DHPVELLARD FEKNYNMYIF
PVHWQFGQLD QHPIDGYLSH TELAPLRAPL IPMEHCTTRF FETCDLDNDK YIALDEWAGC
FGIKQKDIDK DLV

Purity: > 95 % by SDS-PAGE and HPLC analyses.

Endotoxin Level: Level Less than 1EU/µg of rHuSPARC as determined by LAL method

Target Details

Target: SPARC

Alternative Name: SPARC ([SPARC Products](#))

Background: SPARC, an acronym for 'secreted protein, acidic and rich in cysteine', is also known as osteonectin or BM-40. It is the founding member of a family of secreted matricellular proteins with similar domain structure. The 303 amino acid, 43 kDa protein contains a 17 aa signal sequence, an N-terminal acidic region that binds calcium, a follistatin domain containing Kazal-

Target Details

like sequences, and a C-terminal extracellular calcium (EC) binding domain with two EF-hand motifs. SPARC is produced by fibroblasts, capillary endothelial cells, platelets and macrophages, especially in areas of tissue morphogenesis and remodeling. SPARC shows context-specific effects, but generally inhibits adhesion, spreading and proliferation, and promotes collagen matrix formation. For endothelial cells, SPARC disrupts focal adhesions and binds and sequesters PDGF and VEGF. SPARC is abundantly expressed in bone, where it promotes osteoblast differentiation and inhibits adipogenesis. Synonym: SPARC, Human.
Formulation: Lyophilized from a 0.2µm filtered concentrated (1mg/ml) solution in 1×PBS, pH 7.4.

Molecular Weight: Approximately 34.0 kDa, a single non-glycosylated polypeptide chain containing 286 amino acids, with expression vector sequence (containing 6 × His tag).

Pathways: [Autophagy](#)

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions.

Storage: 4 °C